Abstract
According to hieroglyphic evidence, diarrhea is one of the oldest recorded illnesses, dating as far back as 3300 bc [1]. However, despite major discoveries in microbiology during the past century, the etiology of most diarrheal illnesses remained elusive until relatively recently [2, 3]. Although volunteer studies in the 1940s and 1950s showed that oral administration of bacteria-free stool filtrates derived from patients with diarrhea could induce illness, a suspected viral etiologic agent could not be identified.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
Editor’s note: As of 2011, both new vaccines have demonstrated efficacy in developing countries and Rotarix is widely used in Latin America.
References
Kumate J, Isibasi A. Pediatric diarrheal diseases: a global perspective. Pediatr. Infect Dis. 1986; 5(Suppl): S21–28
Connor JD, Barrett-Connor E. Infectious Diarrheas. Pediatr Clin North Am 1967;14:197–221
Yow MD, Melnick JL, Blattner RJ, Stephenson NB, Robinson NM, Burkhardt MA. The association of viruses and bacteria with infantile diarrhea. Am J Epidemiol 1970;92:33–39
Kapikian AZ. The discovery of the 27-nm Norwalk Virus: an historic perspective. J. Infect Dis 2000;181 (Suppl 2) 295–302
Kapikian AZ, Wyatt RG, Dolin R, Thornhill TS, Kalica AR, Chanock RM. Visualization by immune electron microscopy of a 27 nm particle associated with acute nonbacterial gastroenteritis. J. Virol 1972;10:1075–1081
Bishop RF, Davidson GP, Holmes IH, Ruck BJ. Virus particles in epithelial cells of duodenal mucosa from children with acute non-bacterial gastroenteritis. Lancet 1973;302:1281–1283
Green KY. Caliciviridae: The Noroviruses. In Fields Virology, Knipe DM, Howley PM (eds) (Fifth Ed) 2007; pp 949–97 Lippincott Williams & Wilkins, Philadelphia
Estes MK, Kapikian. Rotaviruses. in Fields Virology, Knipe DM, Howley PM (eds) (Fifth Ed) pp 1917–1974 (Lippincott Williams & Wilkins, Philadelphia)
Patel MM, Widdowson M-A, Glass RI, Akazawa K, Vinje J, Parashar UD. Systematic literature review of role of noroviruses in sporadic gastroenteritis. Emerg Infect Dis 2008;14:1224–1231
Editorial. More about D and V. Brit. Med J 1974; 5935;1–2
Institute of Medicine. The prospects for immunizing against rotavirus. In New Vaccine Development. Establishing Priorities. Diseases of importance in Developing Countries. (1986). Vol 2: pp 308–316. National Academy Press, Washington
Institute of Medicine. The prospects for immunizing against rotavirus. In New Vaccine Development. Establishing Priorities. Diseases of importance in the United States. (1986). Vol 1: pp 410–423. National Academy Press, Washington
Parashar UD, Burton A, Lanata C, Boschi-Pinto C, Shibuya K, Steele D, Birmingham M, Glass RI. Global mortality associated with rotavirus disease among children in 2004. J Infect Dis 2009;200 (Suppl 1):9–15
Glass RI, Parashar UD, Bresee JS, Turcios R, Fischer TK, Widdowson M-A, Jiang B, Gentsch JR. Rotavirus vaccines: current prospects and future challenges. Lancet 2006;368:323–332
Flewett TH, Bryden AS, Davies H, Woode GN, Bridger JC, Derrick JM. Relation between viruses from acute gastroenteritis of children and newborn calves. Lancet 1974; 304: 61–63
Prasad BVV. In Rotaviruses. Current Topics in Microbiology and Immunology 1994; 185:Cover (adapted from). Ramig RF (ed) Springer, Berlin
Kapikian AZ, Wyatt RG, Levine MM, Yolken RH, Van Kirk DH, Dolin R, Greenberg HB, Chanock RM. Oral administration of a human rotavirus to volunteers: induction of illness and correlates of resistance. J. Infect Dis 1983; 147:95–106
Kapikian AZ, Wyatt RG, Levine MM, Black RE, Greenberg HB, Flores J, Kalica AR, Hoshino Y, Chanock RM. Studies in volunteers with human rotaviruses. Develop. Biol. Standard 1983;53;209–2218
Wyatt RG, James WD, Bohl EH, Theil KW, Saif LJ, Kalica AR, Greenberg HB, Kapikian AZ, Chanock RM. Human rotavirus type 2: cultivation in vitro. Science 1980;207:189–191
Wyatt RG, Kapikian AZ, Greenberg HB, Kalica AR, Flores J, Hoshino Y, Chanock RM, Levine MM. Development of vaccines against rotavirus disease. Prog Fd Sci 1983;7:189–192
Wyatt RG, Kapikian AZ, Hoshino Y, Flores J, Midthun K, Greenberg HB, Glass RI, Askaa J, Levine MM, Black RE, Clements ML, Potash L, London WT. Development of rotavirus vaccines. Control and eradication of infectious diseases an international d symposium PAHO copublication series No. 1 1985; pp 17–38
Kapikian AZ, Wyatt RG, Greenberg HB, Kalica AR, Kim HW, Brandt CD, Rodriguez WJ, Parrott RH, Chanock RM. Approaches to immunization of infants and young children against gastroenteritis due to rotaviruses. Rev Infect Dis 1980;2;459–469
Woode GN, Jones J, Bridger J. Levels of colostral antibodies against neonatal calf diarrhea virus. Vet Rec 1975;96:148–149
Bridger JC, Woode GN. Neonatal calf diarrhea: Identification of a reovirus-like (rotavirus) agent in faeces by immunofluorescence and immune electron microscopy. Br Vet J 1975; 131;528–535
Snodgrass DR, Wells PW. Rotavirus infection in lambs: studies on passive protection. Arch Virol 1976; 52:201–205
Snodgrass DR, Madeley CR, Wells PW, Angus KW. Human rotavirus in lambs: infection and passive protection. Infect Immun 1977;16:268–270
Snodgrass DR, Wells PW. Passive immunity in rotavirus infections. J Am Vet Med Assoc 1978;173:L565–569
Lecce JG, King MW, Mock R. Reovirus-like agent associated with fatal diarrhea in neonatal pigs. Infect Immun 1976;14:816–825
Flores J, Perez-Schael I, Blanco M, Garcia D, Vilar M, Cunto W, Gonzalez R, Ubina C, Boher J, Mendez M, Kapikian AZ. Comparison of the reactogenicity and antigenicity of the M37 rotavirus vaccine and the rhesus-rotavirus-based quadrivalent vaccine. Lancet 1980; 336:330–334
Vesikari T, Ruuska T, Koivu HP, Green KY, Flores J, Kapikian AZ. Evaluation of the M37 human rotavirus vaccine in 2-to 6-month-old infants. Pediatr Infect Dis J 1991;10:912–917
Bishop RF, Barnes GL, Cipriani E, Lund JS. Clinical immunity after neonatal rotavirus infection. N. Eng J. Med 1983;309:72–76
Hoshino Y, Kapikian AZ, Chanock RM. Selection of cold-adapted mutants of human rotaviruses that exhibit various degrees of growth restriction in vitro. J. Virol 1994;68:7598–7602
Treanor JJ. Unpublished studies
Henderson DA. Edward Jenner’s vaccine. Publ. Hlth Reports 1997:112: 116–121. (Reprinted from The Jordan Report: Accelerated Developments of Vaccines 1996, NIAID, NIH)
Woode GN, Bridger JC, Jones JM, Flewett TH, Bryden AS, Davies HA, White GBB. Morphological and antigenic relationships between viruses (rotaviruses) from acute gastroenteritis of children, calves, piglets, mice and foals. Infec Immun 1976;14:804–810
Kapikian AZ, Cline WL, Kim HE, Kalica AR, Wyatt RG, Van Kirk DH, Chanock RM, James HD Jr, Vaughn AL. Antigenic relationships among the five reovirus-like (RVL) agents by complement fixation (CF) and development of a new substitute CF antigen for the human RVL agent of infantile gastroenteritis. Proc Soc Exp Biol Med 1976;152:535–539
Matsuno S, Inouye S, Kono R. Plaque assay of neonatal calf diarrhea virus and the neutralizing antibody in human sera. J. Clin Microbiol 1977;5:1–4
Wyatt RG, Mebus CA, Yolken RH, Kalica AR, James HD Jr, Kapikian AZ, Chanock RM. Rotaviral immunity in gnotobiotic calves: heterologous resistance to human virus induced by bovine virus. Science 1979;203:548–550
Wyatt RG, Kapikian AZ, Mebus CA. Induction of cross-reactive serum neutralizing antibody to human rotavirus in calves after in utero administration of bovine rotavirus. J Clin Microbiol 1983;18;505–508
Zissis G, Lambert JP, Marbehant P, Marissens D, Lobman M, Charlier P, Delem A, Zygraich N. Protection studies in colostrum-deprived piglets of a bovine rotavirus vaccine candidate using human rotavirus strains for challenge. J Infect Dis 1983;148:1061–1068
Vesikari T, Isolauri E, Delem A, D’Hondt E, Andre FE, Zissis G. Immunogenicity and safety of live oral attenuated bovine rotavirus vaccine strain RIT 4237 in adults and young children. Lancet 1983;322;807–811
Vesikari T, Isolauri E, D’Hondt E, Delem A, Andre FE, Zissis G. Protection of infants against rotavirus diarrhoea by RIT 4237 attenuated bovine rotavirus strain vaccine. Lancet 1984;323:977–981
Vesikari T, Isolauri E, Delem A, D’Hondt E, Andre A, Beards GM, Flewett TH. Clinical efficacy of the RIT 4237 live attenuated bovine rotavirus vaccine in infants vaccinated before a rotavirus epidemic. J. Pediatr 1985;107:189–194
Kapikian AZ, Hoshino Y, Flores J, Midthun K, Glass RI, Nakagomi O, Nakagomi T, Chanock RM, Potash L, Levine MM, Dolin R, Wright PF, Belshe RE, Anderson EL, Vesikari T, Gothefors L, Wadell G, Perez-Schael I. Alternative approaches to the development of a rotavirus vaccine. In: Development of Vaccines and Drugs against Diarrhea. 11th Nobel Conf., Stockholm 1985, pp 192–214 (eds J. Holmgren, A Lindbergh & R Mollby) Studentlitteratur, Lund, Sweden, 1986
Stuker G, Oshiro L, Schmidt NL. Antigenic comparisons of two new rotaviruses from rhesus monkeys. J. Clin. Microbiol 1980; 11:202–203
Kapikian AZ, Midthun, K, Hoshino Y, Flores J, Wyatt RG, Glass RI, Askaa J, Nakagomi O, Nakagomi T, Chanock RM, Levine MM, Clements ML, Dolin R, Wright PF, Belshe RB, Anderson EL, Potash L. Rhesus rotavirus: a candidate vaccine for prevention of human rotavirus disease, In: Vaccines 85 pp 357–367. Cold Spring Harbor Laboratory
Wallace RE, Vasington PJ, Petricciani JC, Hopps HE, Lorenz DE, Kadanka Z. Development of a diploid cell line from fetal rhesus monkey lung for virus vaccine production. In Vitro 1973;8:323–332
Kapikian AZ, Flores J, Hoshino Y, Midthun K, Green KY, Gorziglia M, Chanock RM, Potash L, Perez-Schael I, Gonzalez M, Vesikari T, Gothefors L, Wadell G, Glass RI, Levine MM, Rennels MB, Losonsky G, Christy C, Dolin R, Anderson EL, Belshe RB, Wright PF, Santosham M, Halsey NA, Clements ML, Sears SD, Steinhoff MC, Black RE. Rationale for the development of a rotavirus vaccine for infants and young children. In: Progress in Vaccinology 1989 Vol 2 pp 151–180 (GP Talwar ed). Springer, New York
Christy C, Madore HP, Treanor JJ, Pray K, Kapikian AZ, Chanock RM, Dolin R. Safety and immunogenicity of live attenuated rhesus monkey rotavirus vaccine. J. Infect Dis. 1986;154:1045–1047(correspondence)
Losonsky GA, Rennels MB, Kapikian AZ, Midthun K, Ferra PJ, Fortier DN, Hoffman KM, Baig A, Levine MM. Safety, infectivity, transmissibility and immunogenicity of rhesus rotavirus vaccine (MMU 18006) in infants. Pediatr Infect Dis 1986; 5:25–29
Anderson EL, Belshe RB, Bartram J, Crookshanks-Newman F, Chanock RM, Kapikian AZ. Evaluation of rhesus rotavirus vaccine (MMU 18006) in infants and young children. J. Infect Dis 1986;153:823–831
Perez-Schael I, Gonzalez M, Daoud N, Perez M, Soto I, Garcia D, Daoud G, Kapikian AZ, Flores J. Reactogenicity and antigenicity of the rhesus rotavirus vaccine in Venezuelan children. J. Infect Dis 1987;155;334–338
Rennels MB, Losonsky GA, Schindledecker CL, Hughes TP, Kapikian AZ, Levine MM, the Clinical Study Group (Ferra PJ, Fortier DN, Sutton JM). Immunogenicity and reactogenicity of lowered doses of rhesus rotavirus vaccine strain MMU 18006 in young children. Pediatr Infect Dis J. 1987; 6:260–267
Wright PF, Tajima T, Thompson J, Kokubun K, Kapikian A, Karzon DT. Candidate rotavirus vaccine (rhesus rotavirus strain) in children: an evaluation. Pediatrics 1987;80:473–480
Losonsky GA, Rennels MB, Lim Y, Krall G, Kapikian KZ, Levine MM. Systemic and mucosal responses to rhesus roavirus vaccine MMU 18006. Pediatr Infect Dis J 1988;7:388–393
Vesikari T, Kapikian AZ, Delem A, Zissis. A comparative trial of rhesus monkey (RRV-1) and bovine (RIT 4237) oral rotavirus vaccines in young children. J. Infect Dis 1986;153:832–839
Kapikian AZ, Flores J, Midthun K, Hoahino Y, Green KY, Gorziglia M, Nishikawa K, Chanock RM, Potash L, Perez-Schael I. Strategies for the development of a rotavirus vaccine against infantile diarrhea with an update on clinical trials of rotavirus vaccine. Adv Exp Med Biol 1987;257:67–89
Rennels MB, Losonsky GA, Levine MM, Kapikian AZ, and the Clinical Study Group (Fortier DN, Sutton JM, Ferra PJ and Hoffman KM) Preliminary evaluation of the efficacy of rhesus rotavirus vaccine strain MMU 18006 in young children. Pediatr Infect Dis 1986;5:587–588
Flores J, Perez-Schael I, Gonzalez M, Garcia D, Perez M, Daoud N, Cunto W, Chanock RM, Kapikian AZ. Protection against severe rotavirus diarrhoea by rhesus rotavirus vaccine in Venezuelan infants. Lancet 1987;329; 882–884
Gothefors L, Wadell G, Juto P, Taniguchi K, Kapikian AZ, Glass RI. Prolonged efficacy of rhesis rotavirus vaccine in Swedish children. J Infect Dis 1989;159:753–757
Rennels MB, Losonsky GA, Young AE, Shindledecker CL, Kapikian AZ, Levine MM and the Clinical Study Group. An efficacy trial of rhesus rotavirus vaccine in Maryland. Am J Dis Child 1990;144:601–604
Christy C, Madore HP, Pichichero ME, Gala C, Pincus P, Vosefski D, Hoshino Y, Kapikian AZ, Dolin R. The Elmwood and Panorama pediatric groups: field trial of rhesus rotavirus vaccine in infants. Pedaitr Infect Dis J 1988;7:645–650
Perez-Schael I, Garcia D, Gonzalez M, Gonzalez R, Daoud N, Perez M, Cunto W, Kapikian AZ, Flores J. Prospective study of diarrheal diseases in Venezuelan children to evaluate the efficacy of rhesus rotavirus vaccine. J. Med Virol 1990;30:219–229
Santosham M, Letson GW, Wolff M, Reid R, Gahagan S, Adams R, Callahan C, Sack RB, Kapikian AZ. A field study of the safety and efficacy of two candidate rotavirus vaccines in a Native American population. J. Infect Dis 1991;163: 483–487
Vesikari T, Rautanen T, Varis T, Beards GM, Kapikian AZ. Rhesus rotavirus candidate vaccine. Clinical trial in children vaccinated between 2 and 5 months of age. Am J Dis Child 1990;144:285–289
Madore, HP, Christy C, Pichichero M, Long C, Pincus P, Vosefsky P, Kapikian AZ, Dolin R, Elmwood, Panorama, and Westfall Pediatric Groups. Field trial of rhesus rotavirus or human-rhesus reassortant vaccine of VP7 serotype 3 or 1 specificity in infants. J. Infect Dis 1992;166:235–243
Kapikian AZ, Flores J, Midthun K, Hoshino Y, Green KY, Gorziglia M, Taniguchi K, Nishikawa K, Chanock RM, Potash L, Perea-schael I, Dolin R, Christy C, Santosham M, Halsey N, Clements ML, Sears SD, Black RE, Levine MM, Losonsky GA, Rennels MB, Gothefors L, Wadell G, Glass RI, Vesikari T, Anderson EL, Belshe RB. Wright PF, Urasawa. Development of a rotavirus vaccine by a “Jennerian” and a modified “Jennerian” approach. In: Modern Approaches to New Vaccines including Prevention of AIDS: Cold Spring Harbor Laboratory. Vaccines 88; 1988 pp 151–159
Lanata C, Black RE, Flores J, Lazo F, Butron B, Linhares A, Huapaya A, Ventura G, Gil A, Kapikian AZ. Immunogenicity, safety and protective efficacy of one dose of the rhesus rotavirus vaccine and serotype 1 and 2 human-rhesus rotavirus reassortants in children from Lima, Peru. Vaccine 1996;14:237–243
Kapikian AZ, Flores J, Hoshino Y, Midthun K, Gorziglia M, Green KY, Chanock RM, Potash L, Sears SD, Clements ML, Halsey NA, Black RE, Perez-Schael I. Prospects for development of a rotavirus vaccine against rotavirus diarrhea in infants and young children. Rev. Infect Dis (Suppl) 1989;3:539–546
Midthun K, Greenberg HB, Hoshino Y, Kapikian AZ, Wyatt RG, Chanock RM, Reassortant rotaviruses as potential live roavirus vaccine candidates. J Virol 1985;53: 949–954
Midthun K, Hoshino Y, Kapikian AZ Chanock RM. Single gene substitution rotavirus reassortants containing the major neutralization protein (VP7) of human rotavirus serotype 4. J Clin Microbiol 1986;24: 822–836
Kapikian AZ, Hoshino Y. To serotype or not to serotype: that is still the question. J. Infect. Dis 2007;195:611–614
Kapikian AZ, Hoshino Y, Chanock RM, Perez-Schael I. Efficacy of a quadrivalent rhesus rotavirus-based human rotavirus vaccine aimed at preventing severe rotavirus diarrhea in infants and young children. J. Infect Dis 1996;174 (suppl):65–72
Kapikian AZ, Vesikari T, Ruuska T, Madore HP, Christy C, Dolin R, Flores J, Green KY, Davidson BL, Gorziglia M, Hoshino Y, Chanock RM, Midthun K, Perez-Schael I. An update on the “Jennerian” and modified “Jennerian” approach to vaccination of infants and young children against rotavirus diarrhea. Adv Exp Med Biol 1992; 327:59–69
Kapikian AZ. Rotavirus vaccine: the clinical experience with the rhesus rotavirus-based vaccines. In: Mucosal Vaccines New Trends in Immunization 1996 pp 345–356 (Kiyono H, Ogra PL, McGhee JR eds)
Flores J, Perez-Schael I, Blanco M, Vilar M, Daoud N, Midthun K, Kapikian AZ. Reactions to and antigenicity of two human-rhesus rotavirus reassortant vaccine candidates of serotypes 1 and 2 in Venezelan infants. J. Clin. Microbiol 1989: 27; 512–518
Halsey NA, Anderson EL, Sears SD, Steinhoff M, Wilson M, Belshe RB, Midthun K, Kapikian AZ, Chanock RM, Samorodin R, Burns B, Clements ML. Human-rhesus reassortant vaccines: safety and immunogenicity in adults, infants and children. J. Infect Dis 1988;158:1261–1267
Perez-Schael I, Blanco M, Vilar M,Garcia D,Gonzalez R, Kapikian AZ, Flores J. Clinical studies of a quadrivalent rotavirus vaccine in Venezuelan infants J. Clin Microbiol 1990; 28: 553–558
Flores J, Perez-Schael I, Blanco M, Rojas AM, Alfonzo E, Cespo I, Cunto W, Pittman AL, Kapikian AZ. Reactogenicity and immunogenicity of a high-titer rhesus rotavirus-based quadrivalent rotavirus vaccine. J. Clin Microbiol 1993;31:2439–2445
Linhares AC, Gabbay YB, Mascarenhas JDP, de Freitas RB, Oliveira CS, Bellesi N, Monteiro TA, Lins-Lainson Z, Ramos FLP, Valente SA. Immunogenicity, safety and efficacy of tetravalent rhesus-human, reassortant rotavirus vaccine in Belem, Brazil. Bull WHO 1996:74;491–500
Linhares AC, Lanata CF, Hausdorff WP, Gabbay YB, Black RE. Reappraisal of the Peruvian and Brazilian lower titer tetravalent rhesus-human reassortant rotavirus vaccine efficacy trials: analysis by severity of diarrhea. Pediatr Infect Dis J 1999;18:1001–1006
Kapikian AZ, Flores J, Vesikari T, Ruuska T, Madore HP, Green KY, Gorziglia M, Hoshino Y, Chanock RM, Midthun K, Perez-Shael I. Recent advances in development of a rotavirus vaccine for prevention of severe diarrheal illness of infants and young children. In: Immunology of milk and the neonate 1991 pp 255–264 (Mestecky J et al eds). Plenum Press, New York
Bernstein DI, Glass RI, Rodgers G, Davidson BL, Sack DA, US Rotavirus Vaccine Efficacy Group. Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in US children. JAMA 1985; 273:1191–1196
Vesikari T, Ruuska T, Green KY, Flores J, Kapikian AZ. Protective efficacy against serotype 1 rotavirus diarrhea by live oral rhesus-human reassortant rotavirus vaccines with human rotavirus serotype 1 or 2 specificity. Pediatr Infect Dis J 1992;11:535–542
Rennels MB, Glass RI, Dennehy PH, Bernstein DI, Pichichero ME, Zito ET, Mack ME, Davidson BL, Kapikian AZ for the United States otavirus Efficacy Group. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines-report of the national multicenter trial. Pediatrics 1996; 97: 7–13
Joensuu J, Koskenniemi E, Pang X-L, Vesikari T. Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe gastroenteritis. Lancet 1997;350:1205–1209
Perez-Schael I, Guntinas MJ, Perez M, Pagone V, Rojas AM, Gonzalez R, Cunto W, Hoshino Y, Kapikian AZ. Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela N. Eng. J. Med 1997;337: 1181–1187
Santosham M, Moulton LH, Reid R, Croll J, Weatherbolt R, Ward R, Forro J, Zito E, Mack M, Brenneman G, Davidson BL. Efficacy and safety of high-dose rhesus-human reassortant vaccine in Native American populations. J Pediatr 1997;131: 632–638
Centers for Disease Control and Prevention. Rotavirus vaccine for the prevention of rotavirus gastroenteritis among children: recommendation of the Advisory Committee on Immunization Practices (ACIP). MMWR 1999;48:577–581
Centers for Disease Control and Prevention. Intussusception among recipients of rotavirus vaccine: United States, 1998–1999. MMWR 1999;48:577–581
Centers for Disease Control and Prevention. Withdrawal of rotavirus vaccine recommendation. MMWR 1999;48:1007
Mato SP, Perrin K, Scardino D, Begue RE. Evaluation of rotavirus vaccine effectiveness in a pediatric group practice. Am J. Epidem 2002;156:1049–1055
Staat MA, Cortese MM, Bresee JS, Begue RE, Vitek C, Rhodes P, Zhang R, Gentsch J, Roberts NE, Jaeger JL, Wars R, Bernstein DI, Dennehy PH. Rhesus rotavirus vaccine effectiveness and factors associated with receipt of vaccine. Pediatr Infect Dis 2006; 25:1013–1016
Tate JE, Curns AT, Cortese MM, Weintraub ES, Hambidge S, Zangwill KM, Patel MM, Baggs JM, Parashar UD. Burden of acute gastroenteritis hospitalizations and emergency department visits in US children that is potentially preventable by rotavirus vaccination: a probe study using the now withdrawn RotaShield vaccine. Pediatrics 2009;123:744–749
Kapikian AZ. A rotavirus vaccine for preventing severe diarrhoea of infants and young children: development and withdrawal. In: Chadwick D, Goode JA, eds. Gastroenteritis viruses. Novartis Foundation Symposium 238. Chichester, England. John Wiley and Sons. 1001; 153–171
ACIP. Verbatim transcript of the ACIP meeting (Atlanta GA), 22 October 1999 Nancy Lee and Associates, Certified Cour Reporters 1999;3:1–174
Murphy BM, Morens DM, Simonsen L, Chanock RM, La Montagne JR, Kapikian AZ. Reappraisal of the association of intussusception with the licensed live rotavirus vaccine challenges initial conclusions J. Infect Dis 2003;187: 1301–1308
Murphy TV, Gargiullo PM, Massoudi MS et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 2001;344:564–572
Murphy TV, Gargiullo PM, Massoudi MS, et al. Corrections: intussusception among infants given an oral rotavirus vaccine. N Engl Med 2001;344:1564
Kramarz P, France EK, Destefano F, et al. Population-based study of rotavirus vaccination and intussusception. Pediatr Infect Dis J 2001;20:410–416
Simonsen L, Morens D, Elixhauser A, Gerber M,Van Raden M, Blackwelder W. Effect of rotavirus vaccination programme on trends in admission of patients to hospital for intussusception. Lancet 2001;358;1224–1229
Hall AJ. Ecological studies and debate on rotavirus vaccine and intussusception. Lancet 2001;358:1197–1198 (Commentary)
Kapikian AZ. Ecological studies, rotavirus vaccination, and intussusception. Lancet 2002;359:1065–1066 (letter)
Hall AJ. Ecological studies, rotavirus vaccination, and intussusception. Lancet 2002;359:1066 (letter)
Simonsen L, Morens DM, Blackwelder WC. Ecological studies, rotavirus vaccination, and intussusception. Lancet 2002;359:1066–1067 (letter)
Murphy TV, Gargiullo PM, Wharton M. More on Rotavirus Vaccination and Inussusception. N. Engl. J Med 2002;346: 211–212 (letter)
Centers for Disease Control and Prevention Advisory Committee on Immunization Practice. Records of the meeting held on February 20–21, 2002, Atlanta Marriott North Central Hotel, Atlanta
Gay N, Ramsay M, Waight P. Rotavirus vaccination and intussusception. Lancet 1999;354: 956 (Letter)
Pang LC. Intussusception revisited: clinicopathologic analysis of 261 cases, with emphasis on pathogenesis. South. Med J 1989; 82; 215–228
Simonsen L, Viboud C, Elixhauser A, Taylor RJ, Kapikian AZ. More on RotaShield and intussusception: the role of age at the time of vaccination. L. Infect Dis 2005;192 (Suppl 1): 36–42
Kapikian AZ, Simonsen L, Vesikaari T, Hoshino Y, Morens DM, Chanock RM, La Montagne JR, Murphy BM. A hexavalent human rotavirus-bovine rotavirus (UK) reassortant vaccine designed for use in developing countries and delivered in a schedule with the potential to eliminate the risk of intussusception J. Infect Dis 2005;192 (suppl):22–29
Rothman KJ, Young-Xu Y, Arellano F. Age dependence of the relation between reassor-tant rotavirus vaccine (RotaShield) and intussusception. J. Infect Dis 2006: 193:898 (Correspondence)
Rothman KJ, Lee L. Rotashield and intussusception: reanalysis of data demonstrates reduced risk. Chinese J Vaccines and Immunization 2005;11:71–73 (Correspondence)
Simonsen L, Taylor RJ, Elixhauser A, Viboud C, Kapikian AZ. Reply to Rothman et al. J. Infect Dis 2006; 193:898–899 (Correspondence)
Garguillo PM, Murphy TV, Davis RL. Is there a safe age for vaccinating infants with tetravalent rhesus-human reassortant rotavirus vaccine? J. Infect Dis 2006;194:1793–1794 (Correspondence)
Rothman KJ, Arellano FM, Young-Xu Y, Simonsen L, Gargiullo et al. J infect Dis 2006;194;1794–1795
WHO Global Advisory Committee on Vaccine Safety 1-2 December 2005. Rotavirus vaccine safety. Wkly Epid Rec 2006; No 2 vol 81;16–17
Simonsen, L. Unpublished Studies
WHO Position paper Rotavirus Vaccines. Wkly Epid Rep 2007; no 32 vol 82;285–296
Perrin PS, Lindsay FC. Intussusception: a monograph based on 400 cases. Brit J. Surg 1921; 9:46–71
Chen YE, Beasley S, Grimwood K. Intussusception and rotavirus associated hospitalization in New Zealand. Arch Dis Cils. 2005; 10:1077–1081
Justice FA, Auldist AW, Bines JE, Intussusception: trends in clinical presentation and management. J. Gastroenterol Hepatol 2006;21:842–846
Tate JE, Simonsen L, Viboud C, Steiner C, Patel M, Curns AT, Parashar UD. Trends in intussusception hospitalizations among Us infants, 1993–2004: implications for monitoring the safety of the new rotavirus vaccination program. Pediatrics 2008;121: e1125–1132
Vesikari T, Matson DO, Dennehy P et al. Safety and efficacy of a pentavalent human-bovine (WC2) reassortant rotavirus vaccine N. Eng. J. Med 2006;354: 23–33
Simonsen L, Taylor RJ, Kapikian AZ. Rotavirus vaccines. N Engl J Med 2006;354:1748 (letter)
US FDA: FDA public Health Notification: Information on RotaTeq and Intussusception February 13, 2007
Haber P, Patel M, Izurieta HS, Baggs J, Gargiullo P, Weintraub E, Cortese M, Braun MM, Belongia EA, Miller E, Ball R, Iskander J, Parashr U. Pediatrics 2008;121:1206–1212
Ruiz-Palacios GM, Perez-Schael I, Velazquez FR et al. Safety and efficacy of an attenuated vaccine against rotavirus gastroenteritis. No Engl J Med 2006;354:11–22
Bresee JS, El Arifeen S, Azim T, Chakraborty J, Mounts AW, Podder G, Gentsch JR, Ward RL, Black R, Glass RI, Yunus M. Safety and immunogenicity of tetravalent rhesus-based roavirus vaccine in Bangladesh. Ped Inf DIs J 2001;20:1136–1143
Weijer C. The future of research into rotavirus vaccine. Benefits of vaccine may outweigh risks for children in developing countries. BMJ 2000;321:525–526
Ruiz L, Personal Communication
Vesikari T, Karvonen A, Forrest BD, Hoshino Y, Chanock RM, Kapikian AZ. Neonata administration of rhesus rotavirus tetravalent vaccine. Pediatr Infect Dis J 2006;25:118–122
Hoshino Y, Jones RW, Ross J, Kapikian AZ. Construction and characterization of rhesus monkey rotavirus (MMU18006)- or bovine rotavirus (UK)-based serotype G5, G8, G9 or G10 single VP7 gene substitution reassortant candidate vaccines. Vaccine 2003;21:3003–3010
Fauci AS. The expanding global health agenda: a welcome development. Nature Med 2007;13;1169–1171
Sidwell RW. Overview of viral agents in pediatric enteric infections. Pediatr Infect Dis 1986; 5 (Suppl):S44–45
Kapikian AZ, Kim HW, Wyatt RG et al. Reovirus-like agent in stools: association with infantile diarrhea and development of serologic tests. Science 1974;185:1049–1053
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Kapikian, A.Z. (2011). History of Rotavirus Vaccines Part I: RotaShield. In: Plotkin, S. (eds) History of Vaccine Development. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-1339-5_28
Download citation
DOI: https://doi.org/10.1007/978-1-4419-1339-5_28
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-1338-8
Online ISBN: 978-1-4419-1339-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)